Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the stock.

A number of other equities research analysts have also recently weighed in on EKSO. HC Wainwright reduced their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Lake Street Capital dropped their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th.

Ekso Bionics Stock Performance

NASDAQ:EKSO opened at $0.58 on Friday. Ekso Bionics has a 1-year low of $0.50 and a 1-year high of $3.13. The firm has a market capitalization of $12.76 million, a price-to-earnings ratio of -0.89 and a beta of 1.43. The company’s 50-day moving average is $0.80 and its two-hundred day moving average is $1.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter last year, the company earned ($0.24) earnings per share. Analysts forecast that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.